生物技术公司Rebel Medicine完成600万美元A轮融资，以推进非阿片类止痛治疗药物进入临床开发阶段-动脉网

Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

CISION 等信源发布 2025-06-12 22:00



可切换为仅中文







SALT LAKE CITY

盐湖城

，

June 12, 2025

2025年6月12日

/PRNewswire/ -- Rebel Medicine Inc, a clinical‑stage biotechnology company developing innovative drug delivery systems and non‑opioid pain therapeutics for acute and post-operative pain, announced the closing of its

/PRNewswire/ -- Rebel Medicine Inc是一家临床阶段的生物技术公司，致力于开发创新的药物递送系统和非阿片类急性及术后疼痛治疗药物，宣布已完成其

$6 million

600万美元

Series A financing. The Series A financing was led by Crocker Ventures with participation from Central Texas Angel Network (CTAN), Prosperity Solutions Capital, Utah Innovation Fund, SK Hart, the Joan & Tim Fenton Fund, Cantina Angels, and a syndicate of experienced life‑science angel investors. This significant financial milestone coincides with the formal opening of its Investigational New Drug (IND) application with the U.S.

A轮融资。本轮融资由Crocker Ventures领投，Central Texas Angel Network（CTAN）、Prosperity Solutions Capital、Utah Innovation Fund、SK Hart、Joan & Tim Fenton Fund、Cantina Angels以及一群经验丰富的生命科学天使投资人跟投。这一重要的财务里程碑恰逢其向美国正式提交新药临床试验（IND）申请。

Food and Drug Administration (FDA) for Alevatrix™, its lead non-opioid pain drug candidate. The proceeds will fund a first-in-human, randomized, dose-escalation, active-controlled Phase 2 clinical trial in bunionectomy patients to assess the safety and efficacy of Alevatrix™..

食品和药物管理局（FDA）批准了Alevatrix™，其主要的非阿片类止痛药物候选产品。所得资金将用于资助一项针对拇囊炎切除术患者的首次人体、随机、剂量递增、阳性对照的2期临床试验，以评估Alevatrix™的安全性和有效性。

'This is a transformative moment for Rebel Medicine,' said

“这对叛逆医学来说是一个变革性的时刻，”他说

Brett Davis

布雷特·戴维斯

, PhD, Co-Founder and CEO of Rebel Medicine. 'The successful Series A fundraise validates our vision and the potential of our technologies. Coupled with IND clearance for Alevatrix™, it enables us to accelerate clinical development of Alevatrix™ and bring our opioid-sparing pain therapies to patients faster.'.

博士，Rebel Medicine联合创始人兼首席执行官。“A轮融资的成功验证了我们的愿景和我们技术的潜力。加上Alevatrix™的IND批准，这使我们能够加快Alevatrix™的临床开发，并更快地将我们的减少阿片类药物的疼痛疗法带给患者。”

About Alevatrix™

关于Alevatrix™

Alevatrix™ is a novel, long‑acting formulation of bupivacaine, a well‑characterized local anesthetic encapsulated in Rebel Medicine's proprietary injectable matrix. Designed to release drug at the site of administration for up to 72 hours, Alevatrix™ aims to reduce or eliminate the need for opioids after surgery and their associated risks.

Alevatrix™ 是一种新型的长效布比卡因制剂，这种特性良好的局部麻醉剂被封装在Rebel Medicine的专有注射基质中。Alevatrix™ 设计为在给药部位释放药物长达72小时，旨在减少或消除术后对阿片类药物的需求及其相关风险。

In preclinical studies, Alevatrix demonstrated prolonged, multi-day non-opioid analgesia with a favorable safety profile..

在临床前研究中，Alevatrix 展示了持久的、多天的非阿片类镇痛效果，并具有良好的安全性。

About Rebel Medicine Inc

关于叛逆医药公司

Rebel Medicine (

叛逆医学 (

www.rebelmedicine.com

) is a privately held biotechnology company headquartered in

）是一家总部位于私营生物技术公司

Salt Lake City, Utah

犹他州盐湖城

that leverages its proprietary drug delivery technologies to enhance the functionality of validated active pharmaceutical ingredients. This approach leads to novel, high‑value, extended‑release therapeutics that address urgent unmet clinical needs while reducing development time, cost and risk. Rebel Medicine's lead asset, Alevatrix.

利用其专有的药物递送技术来增强已验证活性药物成分的功能。这种方法产生了新颖、高价值、缓释的治疗药物，满足了迫切未满足的临床需求，同时减少了开发时间、成本和风险。 Rebel Medicine 的主要资产 Alevatrix。

™

, is being developed for non-opioid post-operative pain management, with additional pipeline programs in development that utilize Rebel's proprietary delivery systems to provide extended-release of injectable drugs from days to months.

，正被开发用于非阿片类术后疼痛管理，同时还有其他利用Rebel专有递送系统的管线项目正在开发中，这些系统可提供从数天到数月不等的注射药物缓释。

Connect with us on

与我们联系

领英

for future updates.

以备将来更新。

Media Contact

媒体联系人

Brett Davis

布雷特·戴维斯

, PhD — Co‑Founder & CEO

，博士 — 联合创始人兼首席执行官